Gilteritinib Triplet Shows 29.7-Month Median Survival in FLT3-Mutated Acute Myeloid Leukemia – Bioengineer.org

0
1
Advertisment



Gilteritinib Triplet Shows 29.7-Month Median Survival in FLT3-Mutated Acute Myeloid Leukemia  Bioengineer.org



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here